Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month Low – Time to Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $11.62 and last traded at $11.89, with a volume of 3031714 shares trading hands. The stock had previously closed at $12.32.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DYN shares. HC Wainwright decreased their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Robert W. Baird started coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Chardan Capital restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, February 28th. Finally, Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.64.

Dyne Therapeutics Trading Down 3.5 %

The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -3.34 and a beta of 1.11. The stock has a 50-day moving average price of $16.75 and a two-hundred day moving average price of $27.26.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. The trade was a 1.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,387 shares of company stock worth $142,789 in the last 90 days. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $50,000. Neo Ivy Capital Management acquired a new position in Dyne Therapeutics in the fourth quarter valued at approximately $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Dyne Therapeutics by 6.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock valued at $3,378,000 after acquiring an additional 9,029 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in Dyne Therapeutics in the fourth quarter valued at approximately $2,804,000. Finally, Two Sigma Advisers LP lifted its holdings in Dyne Therapeutics by 25.4% in the fourth quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock valued at $1,793,000 after acquiring an additional 15,400 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.